R&D
July 5, 2017
Sym015: A highly efficacious antibody mixture against MET amplified tumors
Clin Cancer Res. 2017 Jul 5. pii: clincanres.0782.2017. doi: 10.1158/1078-0432.CCR-17-0782. [Epub ahead of print]
PMID: 28679766 [PubMed - as supplied by publisher]
PMID: 28679766 [PubMed - as supplied by publisher]
September, 2016
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab
Mol Cancer Ther. 2016 Sep;15(9):2175-86
July, 2016
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
Clin Cancer Res. 2016 Jul 1;22(13):3260-7
May, 2016
Phase I dose-escalation trial of Sym004, a mixture of two anti-EGFR antibodies, in Japanese patients with advanced solid tumors
Journal of Clinical Oncology 34, no. 15_suppl (May 2016) 2522-2522.
February 1, 2016
Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models
Clin Cancer Res. 2016 Feb 1;22(3):633-43
November 19, 2015
Novel antibody–antibiotic conjugate eliminates intracellular S. aureus
Nature 527, 323–328 (2015)
November 19, 2015
Novel antibody–antibiotic conjugate eliminates intracellular S. aureus.
Nature 527, 323–328 (2015)
November 10, 2015
In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography
Oncotarget. 2015 Nov 10;6(35):37486-99